GlassScriptPhysician profile
Ratidzai Rioga
NPI 1437215001
$1,979.79
in general payments reported to CMS, 2019-2025
23 companies · $298 in 2025
The $298 reported for 2025 was more than what 84% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
See the full distribution for Adolescent Medicine (Pediatrics)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $247 · 2021: $369 · 2022: $351 · 2023: $232 · 2024: $335 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $864.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $442.21 | 2020-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $296.28 | 2020-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $227.84 | 2019-2022 | |
| Pfizer INC. | $206.19 | 2019-2025 | |
| Glaxosmithkline, LLC. | $82.96 | 2023-2025 | Bexsero, Pediarix |
| Ironwood Pharmaceuticals, INC | $71.44 | 2024 | |
| Adlon Therapeutics L.P. | $63.46 | 2020-2021 | |
| Tris Pharma INC | $58.46 | 2024-2025 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $52.68 | 2025 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $51.34 | 2022-2024 | Abilify Asimtufii, Abilify Maintena |
| Dermira, INC. | $49.41 | 2020-2021 | |
| Sanofi Pasteur INC. | $48.87 | 2019-2021 | |
| Cranial Technologies, INC | $46.43 | 2024-2025 | Doc Band |
| Seqirus USA INC | $45.30 | 2023-2024 | Flucelvax Quadrivalent, Flucelvax |
| Corium, LLC | $45.13 | 2022-2025 | Azstarys |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $42.24 | 2019 | |
| Neuronetics, INC. | $35.35 | 2025 | Neurostar Tms Therapy System |
| Kowa Pharmaceuticals America, INC. | $29.65 | 2025 | Zoryve |
| Merck Sharp & Dohme LLC | $28.12 | 2023 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Phadia US INC. | $16.43 | 2019 | |
| Abbott Laboratories | $15.51 | 2025 | Id Now Instrument |
| Neurelis, INC. | $13.39 | 2023 | Valtoco |
| Hologic Sales and Service, LLC | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ratidzai Rioga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.